Metastatic Urothelial Tumor ProgressionFollowing First Line Chemotherapy: Prognostic Factors and Importance ofSecond Line Chemotherapy

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Makoseh Mohammad S.; Alwardat Rami A.; Salam Murad Y.; Salah Samer H.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: MIDDLE EAST JOURNAL OF CANCER Year:2018 | Volume:9 | Issue:3 Page(s): 195-201

Download Full-Text

View:

237

Download:

Cites:

Information Journal Paper

Title

Metastatic Urothelial Tumor ProgressionFollowing First Line Chemotherapy: Prognostic Factors and Importance ofSecond Line Chemotherapy

Author(s)

Makoseh Mohammad S. | Alwardat Rami A. | Salam Murad Y. | Salah Samer H. | Issue Writer Certificate

Keywords

Urothelial neoplasms

Prognosis

Chemotherapy

Performance status

Metastatic sites

Abstract

Background: Limited data exists to support the benefit from second-linechemotherapy in patients with metastatic urothelial carcinoma. Factors that predictsurvival following progression after first-line platinum-based regimens in patientstreated outside clinical trials are not clear. This study intends to evaluate differentprognostic factors and the impact of second-line Chemotherapy on survival. Methods: We retrospectively reviewed patients with metastatic urothelial carcinomawho experienced disease progression following first-line platinum-based regimens formetastases. These patients received treatment and follow up visits at a single institution. The effect of demographic, disease characteristics, and second-line therapy on overallsurvival was examined through univariate and multivariate cox-regression analyses. Results: There were 64 patients included. A total of 27 (42%) patients did not receivesecond-line Chemotherapy because of poor Eastern Cooperative Oncology Groupperformance status, 20 (31%) received combination Chemotherapy (platinum-based in17), and 17 (27%) received a single agent Chemotherapy. The median overall survivalfrom the date of documented progression after first-line therapy was 5. 0 months. Inmultivariate analysis, a correlation existed between poor overall survival and performancestatus of ≥ 1 (HR: 5. 74, 95% CI: 1. 4-45. 57, P=0. 036), no second-line Chemotherapy(HR: 2. 72, 95% CI: 1. 39-5. 31, P=0. 003), and ≥ 2 Metastatic sites (HR: 5. 19, 95% CI: 1. 74-15. 44, P<0. 001). Conclusion: A significant proportion of patients with metastatic urothelial carcinomawere not eligible for second-line Chemotherapy because of poor Performance status. Use of second-line Chemotherapy, Eastern Cooperative Oncology Group performancestatus, and number of Metastatic sites were important determinants of survival.

Cites

No record.

References

No record.

Cite

APA: Copy

Makoseh, Mohammad S., Alwardat, Rami A., Salam, Murad Y., & Salah, Samer H.. (2018). Metastatic Urothelial Tumor ProgressionFollowing First Line Chemotherapy: Prognostic Factors and Importance ofSecond Line Chemotherapy. MIDDLE EAST JOURNAL OF CANCER, 9(3), 195-201. SID. https://sid.ir/paper/321245/en

Vancouver: Copy

Makoseh Mohammad S., Alwardat Rami A., Salam Murad Y., Salah Samer H.. Metastatic Urothelial Tumor ProgressionFollowing First Line Chemotherapy: Prognostic Factors and Importance ofSecond Line Chemotherapy. MIDDLE EAST JOURNAL OF CANCER[Internet]. 2018;9(3):195-201. Available from: https://sid.ir/paper/321245/en

IEEE: Copy

Mohammad S. Makoseh, Rami A. Alwardat, Murad Y. Salam, and Samer H. Salah, “Metastatic Urothelial Tumor ProgressionFollowing First Line Chemotherapy: Prognostic Factors and Importance ofSecond Line Chemotherapy,” MIDDLE EAST JOURNAL OF CANCER, vol. 9, no. 3, pp. 195–201, 2018, [Online]. Available: https://sid.ir/paper/321245/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops